About us
Aptarion Biotech is a clinical-stage company that primarily develops its lead drug candidate AON-D21, a complement C5a inhibitor, for the treatment of life-threatening diseases, incl. severe pneumonia and non-small cell lung cancer (NSCLC).
AON-D21 has just demonstrated efficacy in reducing the number of days requiring respiratory support, the length of stay in the intensive care unit, and the total length of hospital stay in two relevant subgroups of patients diagnosed with severe community-acquired pneumonia. The underlying Phase 2 study was conducted in 150 patients in five European countries and the United States. A complete data set, incl. an extensive biomarker analysis, will become available in Nov. 2026.
With its drug candidates, Aptarion leverages the unique properties of mirror-image L-aptamers. L‑Aptamers are single-stranded L-RNA or L-DNA molecules designed to bind and inhibit pharmacologically relevant targets comparable to monoclonal antibodies. They combine high target affinity, specificity, biostability and low immunogenicity with the ease of a scalable chemical production process.
Aptarion is headquartered in Berlin, Germany.
